Format allows scalability and cost reduction; important factors to expand and democratize access to cancer treatment
A became a reference in cancer treatment based on an innovative business model. The company operates as an integrated oncology platform, through strategic partnerships and franchises, which make up a data -centered ecosystem. Drawing allows business scalability and cost reduction, impacting the expansion of reach and democratization of access to treatment. In 2024 alone, 682,000 cancer patients were treated.
The platform also positions the company as a player of high impact on the future of cancer treatment in the country and worldwide. THE expertise Technology is applied to make all patients available to all patients and improve clinical outcomes.
Through an approach data-driven, data based, At the center of the business, it is possible to increase the accuracy of diagnoses and customize treatments. In addition, the company conducts a constant update of protocols. With the aid of AI (artificial intelligence), there is the possibility of performing more effective therapies and reducing side effects, making treatment integrated and individual.
“Cancer is still one of the biggest causes of avoidable death in the 21st century, but not due to lack of technology. A system that allows innovations to reach everyone without exception. This is what we work: make the word ‘remission’ a concrete possibility, not a restricted destination”Said Bruno Ferrari, CEO and founder of Oncoclínicas.
According to the executive, this understanding drives the company to structure a model of service that integrates efficiency and humanized care. “In Oncoclínicas, we challenge traditional paradigms of oncology by proposing a model that balances systemic efficiency and humanization of care. It is not just about innovating, but of questioning: why, in the middle of personalized medicine, millions still face geographical or economic barriers to treat cancer? Our response is on a health platform that operates as a neural network – copying experts, data and updated protocols and protocols dynamically by AI ”, explained Ferrari.
For the CEO, there are those who question artificial intelligence, stating that technology dehumanizes medicine or even occupies the space of professionals. However, according to Ferrari, each algorithm is trained not to replace oncologists, but to amplify their expertise – identifying standards in millions of anonymous cases that a human being would take centuries to analyze. “This is not futuristic; it is democratization of accumulated knowledge.”
In addition to investment in technology and artificial intelligence, the company bets on innovative expansion models for cancer treatment. One of the main examples is the initiative created to treat patients outside the health insurance network.
The proposal is to offer high complexity treatments such as chemotherapy, radiotherapy and infusions, as well as specialized consultations, genetic examinations, image, immunology and pathology, at more affordable prices than other market options.
Another strategic front is the model that expands the presence of Oncoclinicas in regions where access to specialized oncology is still limited. The proposal goes beyond geographical expansion: it is a medical franchise platform that replicates the know-how Clinical, integrated protocols and technical support from the main network, ensuring that the patient receives the same standard of care, regardless of the city where they are being treated.
Each franchised unit operates with continuous supervision and technological integration with the group ecosystem, ensuring adherence to care guidelines, access to molecular panels, 2nd expert opinion and participation in clinical studies. It is a model that combines capillarity, scalability and clinical security – essential pillars to face the challenges of oncology in Brazil.
The challenge of aligning cost and effectiveness
In oncology, the equation between cost and effectiveness has become increasingly complex and worrying. According to the founder and CEO of Oncoclinicas, the major challenge of the sector is to ensure access to the most innovative therapies without compromising the financial sustainability of the health system – both public and supplementary.
“Incorporating state -of -the -art technology cannot be synonymous with economic unfeasibility. It is necessary to rethink financing models, create strategic partnerships that enable scale and efficiency, and adopt systems that value the clinical outcome, not the volume of procedures”, Said Ferrari.
In practice, this means investing in predictive intelligence for more rational use of resources, encouraging early diagnosis and redesigning care flow to reduce waste and late interventions. “When we detect cancer in the early stages, we can not only treat with a greater chance of success, but also avoid exponential costs associated with advanced phases – which are longer, more expensive and profoundly impact the patient’s quality of life.”He added.
This model requires a cultural change that goes beyond assistance: involves health education, easy access to exams and a more active tracking policy. According to Ferrari, it is at this point that initiatives such as awareness campaigns gain protagonism. “We work to anticipate care, not only react to the disease. Informing and educating the population is a primordial step. Sustainability is born from prevention, efficiency and intelligence applied to data”.
By combining technology, scale, and strategic vision, OncoClinicas seeks not only to treat more patients – but to better treat, based on evidence, clinical impact and economic responsibility. A path that, according to the executive, is inevitable for the future of oncology.
International partnerships
The solidity of the oncoclinic business model enables its arrival in Saudi Arabia, inaugurating a new chapter in its trajectory of international expansion. The partnership with the group in 2024 will allow the opening of the 1st Clinic in Riyadh, Saudi Arabia. The unit will guarantee the Saudi population access to state -of -the -art cancer treatments, aligned with the standards of excellence and innovation already established by the Brazilian Company in Latin America.
According to Ferrari, the strategy in Saudi Arabia maintains the pillars that made oncoclinic reference in Brazil, with essential adaptations to the local context. The association between companies is a joint venture –Olonger entrepreneur – which has 51% participation of the Brazilian network and 49% of the Saudi group.
“We apply our expertise in precision management and oncology, respecting cultural particularities, such as the importance of the family in patient care. Furthermore, [outra adaptação é] the training of local professionals to treat prevalent cancers in the region, combining technology and epidemiological knowledge“, These.
In addition to the international unit, the company has an exclusive partnership in Brazil, affiliate of. Collaboration allows oncoclínica to have access to modern approaches and innovative clinical trials related to cancer treatment.
The group still owns, located in Cambridge, United States. The company specializes in bioinformatics, an area that combines biology with computing for biological data processing. Oncoclinicas also has a participation in the institution dedicated to the development and management of clinical studies for independent cancer research in Barcelona, Spain.
When combining know-how International, data culture and innovation with experience gained in millions of care over the last 15 years, OnCoclinicas & Co positions itself as a Brazilian technology -cutting oncology platform and a world reference in the coping of cancer.
This content was produced and paid by .
